Literature DB >> 20861756

Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential.

David Greenberg1, Noga Givon-Lavi, Nitza Newman, Jacob Bar-Ziv, Ron Dagan.   

Abstract

BACKGROUND: We aimed at estimating pneumococcal serotype-specific disease potential in pediatric community-acquired alveolar pneumonia (CAAP), by comparing nasopharyngeal pneumococcal carriage during disease to carriage in healthy children.
METHODS: Pneumococcal nasopharyngeal cultures were obtained from children < 5 years old admitted to the emergency room or hospitalized with radiologically diagnosed CAAP and from healthy controls. Disease potential was estimated by calculating serotype-specific odds ratios (OR) of a given serotype to be carried during disease compared with healthy children (after adjustment for age, ethnicity, previous antibiotic therapy, and season).
RESULTS: A total of 603 and 1504 isolates were obtained from CAAP and healthy children, respectively. A significant OR > 1.0 of a specific serotype being carried during disease (suggesting a higher disease potential) was observed with serotypes (by decreasing rank) 1, 5, 22F, 7F, 14, 9V, and 19A. A significant OR < 1.0 of being carried during disease (suggesting a lower disease potential) was observed with serotypes 6A, 6B, 23A, and 35B. Carriage of PCV7 serotypes (grouped) during CAAP was highest in age group 6 to 17 months. PCV10 and PCV13 provided significantly higher coverage for both 6 to 17 and 18 to 35 month age groups.
CONCLUSIONS: It is suggested that serotypes 1, 5, 7F, 9V, 14, 19A, and 22F have a higher disease potential for childhood pneumonia than do serotypes 6A, 6B, 23A, and 35B.

Entities:  

Mesh:

Year:  2011        PMID: 20861756     DOI: 10.1097/INF.0b013e3181f87802

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  21 in total

1.  Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.

Authors:  Shalom Ben-Shimol; Noga Givon-Lavi; David Greenberg; Ron Dagan
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia.

Authors:  W C Albrich; S A Madhi; P V Adrian; N van Niekerk; T Mareletsi; C Cutland; M Wong; M Khoosal; A Karstaedt; P Zhao; A Deatly; M Sidhu; K U Jansen; K P Klugman
Journal:  Clin Infect Dis       Date:  2011-12-08       Impact factor: 9.079

3.  Risk of invasive pneumococcal disease varies by neighbourhood characteristics: implications for prevention policies.

Authors:  K A Feemster; Y Li; A R Localio; J Shults; P Edelstein; E Lautenbach; T Smith; J P Metlay
Journal:  Epidemiol Infect       Date:  2012-10-31       Impact factor: 2.451

4.  Pediatric osteoarticular infections caused by Streptococcus pneumoniae before and after the introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  C Lemaître; A Ferroni; C Doit; H Vu-Thien; C Glorion; J Raymond; P Mary; P Wicart; E Bingen; B Ilharreborde; M Lorrot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-09       Impact factor: 3.267

5.  Nasal Pneumococcal Density Is Associated with Microaspiration and Heightened Human Alveolar Macrophage Responsiveness to Bacterial Pathogens.

Authors:  Elena Mitsi; Beatriz Carniel; Jesús Reiné; Jamie Rylance; Seher Zaidi; Alessandra Soares-Schanoski; Victoria Connor; Andrea M Collins; Andreas Schlitzer; Elissavet Nikolaou; Carla Solórzano; Sherin Pojar; Helen Hill; Angela D Hyder-Wright; Kondwani C Jambo; Marco R Oggioni; Megan De Ste Croix; Stephen B Gordon; Simon P Jochems; Daniela M Ferreira
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

6.  Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.

Authors:  Olumuyiwa O Odusanya; Yetunde A Kuyinu; Omolara A Kehinde; Fakrudeen Shafi; Nancy François; Juan Pablo Yarzabal; Kurt Dobbelaere; Jens U Rüggeberg; Dorota Borys; Lode Schuerman
Journal:  Hum Vaccin Immunother       Date:  2013-12-04       Impact factor: 3.452

7.  Pneumococcal colonisation density: a new marker for disease severity in HIV-infected adults with pneumonia.

Authors:  Werner C Albrich; Shabir A Madhi; Peter V Adrian; Nadia van Niekerk; Jean-Noel Telles; N Ebrahim; Melina Messaoudi; Glaucia Paranhos-Baccalà; Sven Giersdorf; Guy Vernet; Beat Mueller; Keith P Klugman
Journal:  BMJ Open       Date:  2014-08-11       Impact factor: 2.692

8.  Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric radiologically confirmed community acquired pneumonia following PCV7 introduction in Switzerland.

Authors:  Hélène Chappuy; Kristina Keitel; Mario Gehri; René Tabin; Lynda Robitaille; Frederic Raymond; Jacques Corbeil; Veronica Maspoli; Naim Bouazza; Gabriel Alcoba; Laurence Lacroix; Sergio Manzano; Annick Galetto-Lacour; Alain Gervaix
Journal:  BMC Infect Dis       Date:  2013-07-31       Impact factor: 3.090

9.  Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel.

Authors:  Daniel M Weinberger; Noga Givon-Lavi; Yonat Shemer-Avni; Jacob Bar-Ziv; Wladimir J Alonso; David Greenberg; Ron Dagan
Journal:  Emerg Infect Dis       Date:  2013-07       Impact factor: 6.883

10.  Surveillance of the impact of pneumococcal conjugate vaccines in developing countries.

Authors:  Gail L Rodgers; Keith P Klugman
Journal:  Hum Vaccin Immunother       Date:  2015-08-26       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.